Phase lb dose-finding study of axitinib plus pembrolizumab in treatment-naive patients with advanced renal cell carcinoma

被引：0
|
作者：
Choueiri, Toni K. [1 ]
Plimack, Elizabeth R. [2 ]
Gupta, Shilpa [3 ]
Puzanov, Igor [4 ]
Mcdermott, David F. [5 ]
Tarazi, Jamal [6 ]
Keefe, Stephen [7 ]
Rosbrook, Brad [6 ]
Atkins, Michael B. [8 ]
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA
[3] Univ Minnesota, Mason Canc Ctr, Minneapolis, MN USA
[4] Vanderbilt Univ, Med Ctr, Nashville, TN USA
[5] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA
[6] Pfizer Oncol, San Diego, CA USA
[7] Merck Res Labs, N Wales, PA USA
[8] Georgetown Lombardi Comprehens Canc Ctr, Washington, DC USA
来源：
BJU INTERNATIONAL | 2015年 / 116卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：5 / 5
页数：1
相关论文
共 50 条
  • [31] Pathologic complete response with pembrolizumab plus axitinib in metastatic renal cell carcinoma
    Kazuki Shimizu
    Satoshi Tamada
    Yudai Matsuoka
    Ishun Go
    Satoshi Okumura
    Masao Ogawa
    Tetsuji Ohmachi
    International Cancer Conference Journal, 2022, 11 : 205 - 209
  • [32] HEALTH STATE UTILITIES IN PATIENTS WITH ADVANCED RENAL CELL CARCINOMA RECEIVING FIRST-LINE PEMBROLIZUMAB PLUS AXITINIB OR SUNITINIB
    Bensimon, A.
    Lai, Y.
    Xu, R.
    Bhattacharya, R.
    Shinde, R.
    VALUE IN HEALTH, 2022, 25 (07) : S554 - S554
  • [33] Re: Preliminary Results for Avelumab Plus Axitinib as First-Line Therapy in Patients with Advanced Clear-cell Renal-cell Carcinoma (JAVELIN Renal 100): An Openlabel, Dose-finding and Dose-expansion, Phase 1b Trial
    Gruenwald, Viktor
    Hadaschik, Boris
    EUROPEAN UROLOGY, 2019, 75 (04) : 697 - 698
  • [34] PHASE 3 STUDY OF PEMBROLIZUMAB plus BELZUTIFAN plus LENVATINIB OR PEMBROLIZUMAB/QUAVONLIMAB plus LENVATINIB VERSUS PEMBROLIZUMAB plus LENVATINIB AS FIRST-LINE TREATMENT FOR ADVANCED RENAL CELL CARCINOMA
    Choueiri, Toni
    Plimack, Elizabeth
    Powles, Thomas
    Voss, Martin
    Gurney, Howard
    Silverman, Rachel
    Perini, Rodolfo
    Rodriguez-Lopez, Karla
    Rini, Brian
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A447 - A447
  • [35] Real-world treatment outcomes of first-line axitinib plus pembrolizumab in patients with advanced renal cell carcinoma in the United States.
    Zakharia, Yousef
    Thomaidou, Despina
    Li, Benjamin
    Siu, Gordan
    Levin, Rebecca
    Vlahiotis, Anna
    Zanotti, Giovanni
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [36] Cost-effectiveness of pembrolizumab plus axitinib as first-line therapy for advanced renal cell carcinoma
    Zhu, Jiaxin
    Zhang, Tiantian
    Wan, Ning
    Liang, Zhuoru
    Li, Jiahao
    Chen, Xudong
    Liang, Wenhua
    Jiang, Jie
    IMMUNOTHERAPY, 2020, 12 (17) : 1237 - 1246
  • [37] Angiogenic and Immune-Related Biomarkers and Outcomes Following Axitinib/Pembrolizumab Treatment in Patients with Advanced Renal Cell Carcinoma
    Martini, Jean-Fran Comma Cois
    Plimack, Elizabeth R.
    Choueiri, Toni K.
    McDermott, David F.
    Puzanov, Igor
    Fishman, Mayer N.
    Cho, Daniel C.
    Vaishampayan, Ulka
    Rosbrook, Bradley
    Fernandez, Kathrine C.
    Tarazi, Jamal C.
    George, Saby
    Atkins, Michael B.
    CLINICAL CANCER RESEARCH, 2020, 26 (21) : 5598 - 5608
  • [38] Phase II study of nivolumab and salvage nivolumab plus ipilimumab in treatment-naive patients (pts) with advanced renal cell carcinoma (RCC) (HCRN GU16-260).
    Atkins, Michael B.
    Jegede, Opeyemi
    Haas, Naomi B.
    McDermott, David F.
    Bilen, Mehmet Asim
    Drake, Charles G.
    Sosman, Jeffrey Alan
    Alter, Robert S.
    Plimack, Elizabeth R.
    Rini, Brian, I
    Hurwitz, Michael E.
    Peace, David J.
    Signoretti, Sabina
    Wu, Catherine J.
    Catalano, Paul J.
    Hammers, Hans J.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [39] Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial
    Choueiri, Toni K.
    Larkin, James
    Oya, Mototsugu
    Thistlethwaite, Fiona
    Martignoni, Marcella
    Nathan, Paul
    Powles, Thomas
    McDermott, David
    Robbins, Paul B.
    Chism, David D.
    Cho, Daniel
    Atkins, Michael B.
    Gordon, Michael S.
    Gupta, Sumati
    Uemura, Hirotsugu
    Tomita, Yoshihiko
    Compagnoni, Anna
    Fowst, Camilla
    di Pietro, Alessandra
    Rini, Brian I.
    LANCET ONCOLOGY, 2018, 19 (04): : 451 - 460
  • [40] A phase I/II study of talazoparib and axitinib in patients with advanced clear cell renal cell carcinoma
    Kotecha, Ritesh R.
    Doshi, Sahil D.
    Knezevic, Andrea
    Jacobi, Rachel
    Aggen, David H.
    McHugh, Deaglan Joseph
    Shah, Neil J.
    Carlo, Marie Isabel
    Keegan, Niamh M.
    Gayadin, Yogini
    Chaim, Joshua
    Feldman, Darren R.
    Motzer, Robert J.
    Voss, Martin H.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345